First Manhattan
CLDX icon

First Manhattan’s Celldex Therapeutics CLDX Stock Holding History

First Manhattan’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2
Closed – – 1421
2015
Q3 		$0 Hold
2
– – ﹤0.01% 1431
2015
Q2 		$0 Hold
2
– – ﹤0.01% 1446
2015
Q1 		$0 Hold
2
– – ﹤0.01% 1450
2014
Q4 		$0 Hold
2
– – ﹤0.01% 1480
2014
Q3 		$0 Hold
2
– – ﹤0.01% 1440
2014
Q2 		$0 Hold
2
– – ﹤0.01% 1420
2014
Q1 		$0 Buy
+2
New +$766 ﹤0.01% 1409

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

First Manhattan's CLDX Position: Q4 2015 in Review

First Manhattan sold out of Celldex Therapeutics (CLDX) in Q4 2015, closing a stake of 2 shares.

First Manhattan first reported a position in CLDX in Q1 2014 and held it in 7 quarters. The position peaked at $0 in Q3 2015. 171 funds tracked by Wall St. Rank hold CLDX as of Q4 2015.

  • First Manhattan reported no remaining Celldex Therapeutics position as of Q4 2015 after selling out during the quarter.
  • First Manhattan sold 2 Celldex Therapeutics shares in Q4 2015.
  • First Manhattan first reported a position in Celldex Therapeutics in Q1 2014 and held it in 7 quarters.
  • First Manhattan's Celldex Therapeutics position peaked at $0 in Q3 2015.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2015.

Based on First Manhattan's 13F filing for Q4 2015, filed 20 Jan 2016.